

Servier to Cease Worldwide Production and Supply of Protelos® ▼ (strontium ranelate)

Stoke Poges (UK), Wednesday, 31st May 2017 – Servier UK announces that the global company, Servier, is to cease the worldwide production and supply of Protelos (strontium ranelate).

Protelos (strontium ranelate) is licensed for the treatment of severe osteoporosis:

- in postmenopausal women,
- in adult men,

at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures. The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks.¹

On the 10th February 2017 Servier notified the European Medicine Agency (EMA) and, in the UK, the Department of Health and the MHRA of the intention to cease the marketing and supply of strontium ranelate.

Servier will cease production and distribution of strontium ranelate at the end of August 2017.

This worldwide and strategic decision has been taken for commercial reasons based on the following grounds:

- The restricted indication/limited use of strontium ranelate
- The continuous decrease in the number of patients treated strontium ranelate

Servier UK has been liaising with the relevant patient and professional organisations with an interest in osteoporosis such as the National Osteoporosis Society, the British Society of Rheumatology and the Primary Care Rheumatology Society, to ensure experts in the field of osteoporosis were aware as soon as possible and to enable them to support fellow healthcare professionals and provide advice to patients.

Regulations prohibit Servier from proactively communicating directly with members of the public about their medicine and individual medical advice cannot be provided. Servier suggests that patients who are currently taking strontium ranelate should contact their GP or hospital doctor to discuss their treatment options.

Patients can also obtain general information about the management of osteoporosis and available treatment options from the National Osteoporosis Society at <https://nos.org.uk/>

Healthcare professionals with enquiries may contact Servier UK by emailing medical.information-uk@servier.com or calling 01753 666409.

ENDS

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Health professionals are asked to report any suspected adverse drug reactions.

See www.mhra.gov.uk/yellowcard for how to report side effects.

Servier UK Media Contact: Tel: +44 (0) 1753 662744

Email: pressoffice-UK@servier.com

Servier UK Medical Information: Tel: +44 (0) 1753 666409

Email: medical.information-uk@servier.com

Notes to Editor

About Protelos® (strontium ranelate)¹

Strontium ranelate was granted a Marketing Authorisation by the European Medicines Agency in September 2004

Strontium ranelate is an oral treatment for osteoporosis. The granules, in sachets, are taken as a suspension in a glass of water.

Protelos (strontium ranelate) is licensed for the treatment of severe osteoporosis:

- in postmenopausal women,
- in adult men,

at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures. The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks.¹

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric disease, oncology and diabetes, as well as by its activities in high-quality generic drugs.

More information: www.servier.com

References

1. Protelos Summary of product Characteristics. Available at: <https://www.medicines.org.uk/emc/medicine/15410> Last accessed April 2017